Schrodinger, Inc. SDGR
We take great care to ensure that the data presented and summarized in this overview for Schrodinger, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SDGR
View all-
Black Rock Inc. New York, NY8.52MShares$160 Million0.0% of portfolio
-
Bill Gates Bill & Melinda Gates Foundation Trust | Kirkland, Wa6.98MShares$131 Million0.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.84MShares$128 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY3.13MShares$58.7 Million1.79% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl2.45MShares$45.9 Million0.43% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL2.16MShares$40.5 Million0.01% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.16MShares$40.5 Million0.03% of portfolio
-
Baillie Gifford & CO2.12MShares$39.8 Million0.03% of portfolio
-
State Street Corp Boston, MA2.12MShares$39.7 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.99MShares$37.3 Million0.05% of portfolio
Latest Institutional Activity in SDGR
Top Purchases
Top Sells
About SDGR
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Insider Transactions at SDGR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 15
2024
|
Margaret Dugan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,531
-10.21%
|
$26,027
$17.78 P/Share
|
|
Jun 18
2024
|
Arun Oberoi Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Michael Lynton Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Rosana Kapeller Libermann Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Jeffrey Chodakewitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Gary L Ginsberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Richard Friesner Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+0.96%
|
-
|
|
Jun 18
2024
|
Nancy Thornberry Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Jun 18
2024
|
Gary Sender Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+30.77%
|
-
|
|
Mar 06
2024
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
BUY
Exercise of conversion of derivative security
|
Direct |
5,574
+11.7%
|
$22,296
$4.34 P/Share
|
|
Mar 04
2024
|
Geoffrey Craig Porges EVP & CFO |
SELL
Open market or private sale
|
Direct |
3,315
-36.83%
|
$86,190
$26.35 P/Share
|
|
Mar 04
2024
|
Geoffrey Craig Porges EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
|
Mar 04
2024
|
Jenny Herman SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
7,313
+27.71%
|
-
|
|
Feb 12
2024
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
SELL
Open market or private sale
|
Direct |
901
-2.41%
|
$25,228
$28.29 P/Share
|
|
Feb 12
2024
|
Jenny Herman SVP & Controller |
SELL
Open market or private sale
|
Direct |
787
-6.27%
|
$22,036
$28.29 P/Share
|
|
Feb 12
2024
|
Robert Lorne Abel Officer |
SELL
Open market or private sale
|
Direct |
1,205
-11.43%
|
$32,535
$27.55 P/Share
|
|
Feb 12
2024
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
758
-5.96%
|
$21,224
$28.29 P/Share
|
|
Sep 15
2023
|
Jenny Herman SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
4,545
+26.59%
|
$4,545
$1.2 P/Share
|
|
Aug 09
2023
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
SELL
Open market or private sale
|
Direct |
10,000
-21.1%
|
$400,000
$40.06 P/Share
|
|
Aug 09
2023
|
Margaret Dugan Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 56.3K shares |
|---|---|
| Exercise of conversion of derivative security | 5.57K shares |
| Open market or private sale | 8.5K shares |
|---|